Abilify® Compulsive Behavior Lawsuits
Approved by the U.S. Food and Drug Administration (FDA) in 2002, Abilify® (aripiprazole), is used to treat mental illnesses such as depression, bipolar disorder, schizophrenia, and Tourette syndrome. The drug has been a bestseller, netting $8 billion dollars in sales and reaching 6.5 million prescriptions. Yet despite its widespread use, reports have linked the drug with compulsive behavior in patients, including pathological gambling and hypersexual activity.
If you or someone you love took Abilify and suffered from compulsive gambling or hypersexual behavior, the drug injury lawyers at Ferrer, Poirot & Wansbrough want to help. Our Abilify lawyers are dedicated to fighting for families like yours, and you won’t owe us anything for our services unless we get compensation for you. Don’t wait to get experienced legal help—call or contact us online to get started today.
Abilify® Linked to Poor Impulse Control
Abilify is raking in billions of dollars each year for its manufacturers. However, because of the reported risks of Abilify, European and Canadian regulatory agencies have required drug manufacturers to add warnings to drug packaging.
A report published by the British Journal of Psychology suggests Abilify may overstimulate the reward system in patients’ brains, causing them to develop an impulse control disorder. Pathological gambling, which may include scratch off lottery tickets, casino gambling, or online gambling, has been reported in patients taking Abilify regardless of whether these patients had prior history of gambling.
Compulsive gambling can have adverse effects on patients and their loved ones, including:
- Financial troubles
- Marriage difficulty or divorce
- Property foreclosure
- Problems at work or unemployment
- Damaged reputation
- Emotional distress
FDA Acknowledges Abilify® Compulsive Behavior Side Effects
FDA officials issued a drug safety communication in May 2016 stating that Abilify warning labels will now warn patients that they may experience compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex while taking the drug.
The FDA reports that most patients who experience these urges have no history of compulsive behavior before taking Abilify, and the behaviors tend to stop within days or weeks of stopping the drug or reducing its dosage.
Abilify® Side Effects in the News
A variety of news sources have covered uncontrollable gambling and hypersexual behavior linked to Abilify:
- A Call for Caution on Antipsychotic Drugs – The New York Times, Sept. 2012
- How This Antipsychotic Became America’s Best-Selling Drug – Quartz, Nov. 2014
- Patients Say Abilify Turned Them Into Compulsive Gamblers and Sex Addicts – The Daily Beast, Nov. 2016
We Want to Help With Your Abilify® Lawsuit
Patients who took Abilify and suffered destructive impulse control issues can seek compensation through multidistrict litigation—a type of lawsuit that allows for settlements based on each injury victim’s individual case. Unlike a class action lawsuit, each Abilify victim who meets certain criterial can seek compensation for the types of damages that affected themselves and their families.
If you or someone you love took Abilify and suffered financial losses due to compulsive gambling or experienced personal or professional consequences due to hypersexual behavior, you may be entitled to compensation for:
- Financial losses
- Emotional distress
- Medical fees (if applicable)
- Gambling losses
- Damaged reputation
- Punitive damages
Contact the legal team at Ferrer, Poirot & Wansbrough to get the help you deserve. Give us a call at (800) 210-8503 or fill out our free consultation form.
Abilify® is a registered trademark of Bristol-Myers Squibb and Otsuka America Pharmaceutical, and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with Bristol-Myers Squibb Company; The British Journal of Psychology; The Daily Beast; The New York Times; Otsuka Pharmaceutical Co., Ltd.; Quartz; or the U.S. Food and Drug Administration.